BPC-157 Reference Guide

Compound Reference Overview

Field Value
Name BPC-157
Reference Code BPC-157
Category Healing & Recovery Peptide
Example Strength 10 mg vial (varies by formulation)
Reference Range 250–500 mcg daily; up to 500 mcg twice daily in investigational protocols
Frequency Once or twice daily (literature-based investigational use)
Key Safety Warning Not FDA-approved. Extensive preclinical data with limited human trials. Listed on WADA prohibited substances list. Theoretical concern in active malignancy due to angiogenic activity.

Mechanism of Action (Educational)

BPC-157 (Body Protection Compound) is a synthetic peptide derived from a partial sequence of human gastric juice protein.

Preclinical data suggest it promotes angiogenesis, enhances collagen synthesis, modulates nitric oxide pathways, and may upregulate growth hormone receptor expression in certain tissues.

Animal studies demonstrate accelerated healing of tendon, ligament, muscle, and gastrointestinal tissues. Human data remain limited.

Indications (Investigational)

  • Tendon and ligament injury research
  • Muscle recovery studies
  • Gastrointestinal mucosal healing investigations
  • Post-surgical recovery research

Administration (Literature-Based)

Parameter Details
Route Subcutaneous (near injury site often described)
Frequency Once daily or divided twice daily
Injection Sites Near injury site; abdomen for systemic or GI-focused use
Timing Any time; twice-daily protocols typically spaced ~12 hours apart

Pharmacokinetics (Limited Data)

Estimated half-life is approximately ~4 hours based on limited pharmacologic modeling.

Preclinical healing effects are often observed within 1–2 weeks. Comprehensive human pharmacokinetic data are not well established.

Titration Schedule (Investigational Example)

  • Weeks 1–2: 250 mcg once daily
  • Week 3+: 250–500 mcg daily based on injury severity

Higher protocols may utilize 500 mcg twice daily in select research contexts.

Reconstitution & Concentration (Mathematical Standardization Model)

For educational standardization purposes, concentration may be normalized so that 0.10 mL (10 insulin units) = 500 mcg.

Parameter Value
Diluent Bacteriostatic water
Example Reconstitution 10 mg vial + 2 mL diluent
Resulting Concentration 5 mg/mL (5000 mcg/mL)
Stability Up to 28 days refrigerated (2–8°C; varies by formulation)

Conversion Reference

  • 10 units = 500 mcg
  • 20 units = 1000 mcg (1 mg)
  • 5 units = 250 mcg

This section is provided strictly for arithmetic illustration and does not constitute dosing guidance.

Safety & Contraindications (Summary)

Contraindications

  • Active malignancy (theoretical concern due to angiogenic activity)
  • Pregnancy or breastfeeding

Drug Interactions

  • NSAIDs: Preclinical data suggest potential protective GI effects

Adverse Events

  • Injection site reactions (mild)
  • Nausea (rare)
  • Headache (rare)

Serious Adverse Events

  • Very rare; long-term human safety data remain limited

Monitoring (Investigational)

  • Injury healing progression
  • Gastrointestinal symptom changes (if applicable)
  • Local injection site tolerance

Mathematical Calculation Tool

The calculator below allows mathematical concentration and volume calculations using variable vial strengths and reconstitution volumes. This tool is provided strictly for arithmetic reference.

Peptide Reconstitution Calculator

For Educational & Professional Reference Only

⚠️ This is a mathematical reference tool only. No medical or dosing advice is provided.

Disclaimer

BPC-157 is not FDA-approved for therapeutic use. Available data are primarily preclinical, with limited human studies. This content is provided strictly for educational and professional reference purposes.

Reference Sources